Q-omics provides the consensus-scored CTAGE16P profile across patient tissues and cancer cell-line models. CTAGE16P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CTAGE16P is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, CTAGE16P RNA expression shows 6,227 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, UCEC, and STAD as cancer lineages where CTAGE16P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTAGE16P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTAGE16P survival associations across molecular data types. CTAGE16P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTAGE16P RNA expression–survival associations across cancer types. High CTAGE16P expression shows unfavorable associations in MESO, UVM, DLBC, TGCT, LUAD and CHOL. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CTAGE16P RNA expression.
This table summarizes CTAGE16P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for CTAGE16P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTAGE16P shows lower tumor expression in KICH, KIRC and COAD and higher tumor expression in UCEC. The UCEC box plot shows higher CTAGE16P RNA expression in tumor versus normal tissue (log2 FC = +0.090, t-test p = .012).
This table shows molecular features associated with CTAGE16P in patient tissues and cancer cell lines. In patient samples, CTAGE16P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
